SG2014012108A - 2 -amino-4 -(pyridin-2-yl)-5, 6-dihydro-4h-1, 3-oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors - Google Patents
2 -amino-4 -(pyridin-2-yl)-5, 6-dihydro-4h-1, 3-oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitorsInfo
- Publication number
- SG2014012108A SG2014012108A SG2014012108A SG2014012108A SG2014012108A SG 2014012108 A SG2014012108 A SG 2014012108A SG 2014012108 A SG2014012108 A SG 2014012108A SG 2014012108 A SG2014012108 A SG 2014012108A SG 2014012108 A SG2014012108 A SG 2014012108A
- Authority
- SG
- Singapore
- Prior art keywords
- bace
- pyridin
- dihydro
- inhibitors
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161527172P | 2011-08-25 | 2011-08-25 | |
| US201261665395P | 2012-06-28 | 2012-06-28 | |
| PCT/IB2012/054269 WO2013027188A1 (en) | 2011-08-25 | 2012-08-23 | 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG2014012108A true SG2014012108A (en) | 2014-05-29 |
Family
ID=47018309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2014012108A SG2014012108A (en) | 2011-08-25 | 2012-08-23 | 2 -amino-4 -(pyridin-2-yl)-5, 6-dihydro-4h-1, 3-oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9163011B2 (en) |
| EP (2) | EP2748162B1 (en) |
| JP (1) | JP5816369B2 (en) |
| KR (1) | KR101601571B1 (en) |
| CN (1) | CN103906748B (en) |
| AP (1) | AP2014007507A0 (en) |
| AR (1) | AR087668A1 (en) |
| AU (1) | AU2012298177B2 (en) |
| BR (1) | BR112014004131A2 (en) |
| CA (1) | CA2845093A1 (en) |
| CL (1) | CL2014000458A1 (en) |
| CO (1) | CO6890097A2 (en) |
| CR (1) | CR20140084A (en) |
| EA (1) | EA024580B1 (en) |
| ES (2) | ES2565229T3 (en) |
| GT (1) | GT201400031A (en) |
| HK (1) | HK1195903A1 (en) |
| IL (1) | IL230975A0 (en) |
| MA (1) | MA35356B1 (en) |
| MX (1) | MX339303B (en) |
| PE (1) | PE20141540A1 (en) |
| PL (1) | PL2748162T3 (en) |
| SG (1) | SG2014012108A (en) |
| TN (1) | TN2014000062A1 (en) |
| TW (1) | TW201313706A (en) |
| UY (1) | UY34278A (en) |
| WO (1) | WO2013027188A1 (en) |
| ZA (1) | ZA201401139B (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| RU2012129168A (en) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | OXASINE DERIVATIVES |
| EP2663561B1 (en) | 2011-01-13 | 2016-03-16 | Novartis AG | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
| WO2014065434A1 (en) * | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
| EP2961749B1 (en) * | 2013-03-01 | 2019-10-09 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| CA2903215C (en) | 2013-03-08 | 2021-07-20 | Amgen Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| MA38556A1 (en) * | 2013-04-11 | 2017-09-29 | Hoffmann La Roche | Inhibitors of bace1 |
| JO3318B1 (en) | 2013-06-18 | 2019-03-13 | Lilly Co Eli | Bace inhibitors |
| US20170066741A1 (en) | 2014-02-19 | 2017-03-09 | H. Lundbeck A/S | 2-Amino-3,5,5-Trifluoro-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treatment of Alzheimer's Disease |
| TW201623295A (en) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | Dihydrothiazine and dihydrooxazine derivatives having BACE1 inhibitory activity |
| US9550762B2 (en) | 2014-08-08 | 2017-01-24 | Amgen, Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| JO3458B1 (en) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2-Amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
| MA40941A (en) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-AMINO-5,5-DIFLUORO-6- (FLUOROMETHYL) -6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS |
| CR20170187A (en) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for the treatment of Alzheimer's disease |
| CA2977264C (en) * | 2015-02-25 | 2021-12-07 | Teva Pharmaceuticals International Gmbh | Use of pridopidine to improve cognitive function and for treating alzheimer's disease |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| TW201717948A (en) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines |
| PE20181015A1 (en) | 2015-08-12 | 2018-06-26 | H Lundbeck As | 2-AMINO-3-FLUORO-3- (FLUOROMETHYL) -6-METI-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS |
| JP6616525B2 (en) * | 2016-03-01 | 2019-12-04 | エフ．ホフマン−ラ ロシュ アーゲー | BACE1 inhibitor |
| WO2018112081A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Oxazine derivatives as beta-secretase inhibitors and methods of use |
| EP3555106B1 (en) | 2016-12-15 | 2022-03-09 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
| EP3555085B1 (en) | 2016-12-15 | 2020-12-02 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
| CA3047288A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Thiazine derivatives as beta-secretase inhibitors and methods of use |
| US11021493B2 (en) | 2016-12-15 | 2021-06-01 | Amgen Inc. | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use |
| AU2019258575A1 (en) | 2018-04-27 | 2020-10-29 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity |
| CN109725092A (en) * | 2019-03-19 | 2019-05-07 | 北京和合医学诊断技术股份有限公司 | Detect the liquid phase chromatography analytical method of Ziprasidone content in blood |
| CN113173852B (en) * | 2021-04-26 | 2022-07-12 | 深圳市华先医药科技有限公司 | Preparation method of difluoro malonate type compound |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6911868A (en) | 1968-08-31 | 1970-03-03 | ||
| WO2003006426A1 (en) * | 2001-07-13 | 2003-01-23 | Axxima Pharmaceuticals Ag | Aromatic guanylhydrazones as effective compounds against neurodiseases |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AR044399A1 (en) | 2003-05-20 | 2005-09-14 | Novartis Ag | HETEROCICLICAL COMPOUNDS AND ITS USE AS ACTIVITIES OF PPAR RECEPTORS. PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
| EP1942105B8 (en) | 2005-10-25 | 2014-08-13 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivative |
| KR20100017255A (en) * | 2007-04-24 | 2010-02-16 | 시오노기 앤드 컴파니, 리미티드 | Aminodihydrothiazine derivatives substituted with cyclic groups |
| US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
| EP2360155A4 (en) * | 2008-10-22 | 2012-06-20 | Shionogi & Co | 2-aminopyridin-4-one and 2-aminopyridine derivative both having bace1-inhibiting activity |
| WO2010063718A1 (en) | 2008-12-02 | 2010-06-10 | ETH Zürich | Screening assay for metabolic disease therapeuticals |
| US8461160B2 (en) * | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
| GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| UA108363C2 (en) | 2009-10-08 | 2015-04-27 | IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS | |
| US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
| UA103272C2 (en) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-amino-5,5-difluoro-5,6-dihydro-4h-[1,3]oxazines as bace1 and/or bace2 inhibitors |
| RU2012129168A (en) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | OXASINE DERIVATIVES |
| AU2012206527A1 (en) | 2011-01-13 | 2013-08-01 | Novartis Ag | BACE-2 inhibitors for the treatment of metabolic disorders |
| SG10201601516QA (en) | 2011-01-21 | 2016-03-30 | Eisai R&D Man Co Ltd | Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives |
| US8404680B2 (en) | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
| US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
| CN103608345A (en) | 2011-04-26 | 2014-02-26 | 盐野义制药株式会社 | Oxazine derivative and BACE 1 inhibitor containing same |
| US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
| WO2012168164A1 (en) | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors |
| KR20140041590A (en) | 2011-06-07 | 2014-04-04 | 에프. 호프만-라 로슈 아게 | [1,3]oxazines |
-
2012
- 2012-08-20 UY UY0001034278A patent/UY34278A/en not_active Application Discontinuation
- 2012-08-23 KR KR1020147007405A patent/KR101601571B1/en active IP Right Grant
- 2012-08-23 ES ES12772462.3T patent/ES2565229T3/en active Active
- 2012-08-23 AP AP2014007507A patent/AP2014007507A0/en unknown
- 2012-08-23 ES ES15197854.1T patent/ES2638832T3/en active Active
- 2012-08-23 EA EA201490491A patent/EA024580B1/en not_active IP Right Cessation
- 2012-08-23 PL PL12772462T patent/PL2748162T3/en unknown
- 2012-08-23 PE PE2014000256A patent/PE20141540A1/en not_active Application Discontinuation
- 2012-08-23 BR BR112014004131A patent/BR112014004131A2/en unknown
- 2012-08-23 MX MX2014002230A patent/MX339303B/en active IP Right Grant
- 2012-08-23 CN CN201280052486.2A patent/CN103906748B/en not_active Expired - Fee Related
- 2012-08-23 JP JP2014526591A patent/JP5816369B2/en not_active Expired - Fee Related
- 2012-08-23 US US13/592,580 patent/US9163011B2/en active Active
- 2012-08-23 AU AU2012298177A patent/AU2012298177B2/en not_active Ceased
- 2012-08-23 WO PCT/IB2012/054269 patent/WO2013027188A1/en active Application Filing
- 2012-08-23 SG SG2014012108A patent/SG2014012108A/en unknown
- 2012-08-23 CA CA2845093A patent/CA2845093A1/en not_active Abandoned
- 2012-08-23 EP EP12772462.3A patent/EP2748162B1/en active Active
- 2012-08-23 EP EP15197854.1A patent/EP3023423B1/en active Active
- 2012-08-24 AR ARP120103130A patent/AR087668A1/en unknown
- 2012-08-24 TW TW101130894A patent/TW201313706A/en unknown
-
2014
- 2014-02-11 TN TNP2014000062A patent/TN2014000062A1/en unknown
- 2014-02-13 IL IL230975A patent/IL230975A0/en unknown
- 2014-02-14 ZA ZA2014/01139A patent/ZA201401139B/en unknown
- 2014-02-20 MA MA36766A patent/MA35356B1/en unknown
- 2014-02-21 CO CO14037398A patent/CO6890097A2/en active IP Right Grant
- 2014-02-24 GT GT201400031A patent/GT201400031A/en unknown
- 2014-02-24 CR CR20140084A patent/CR20140084A/en unknown
- 2014-02-25 CL CL2014000458A patent/CL2014000458A1/en unknown
- 2014-09-10 HK HK14109142.2A patent/HK1195903A1/en not_active IP Right Cessation
-
2015
- 2015-02-05 US US14/615,418 patent/US20150150877A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1195903A1 (en) | 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors 2--4-(-2-)-56--4h-13- bace-1 / bace-2 | |
| ZA201308400B (en) | 1,3-oxazines as bace1 and/or bace2 inhibitors | |
| BR112013016360A2 (en) | 1,4 oxazines as inhibitors of bace1 and / or bace2 | |
| IL229686A0 (en) | Halogen -alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors | |
| CO7071122A2 (en) | 1,3-oxazines as inhibitors of bace1 and / or bace2 | |
| BR112013014610A2 (en) | 1,4 oxazines as inhibitors of bace1 and / or bace2 | |
| HK1207369A1 (en) | 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors 5--3h--4- hiv | |
| EP2908825A4 (en) | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
| EP2908824A4 (en) | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
| EP2694521A4 (en) | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
| BR112013020019A2 (en) | 1,4-oxazepines as inhibitors of bace1 and / or bace2. | |
| IL227406A0 (en) | Pyrimidine gyrase and topoisomerase iv inhibitors, compositions comprising the same and uses thereof | |
| HRP20180543T1 (en) | Urea compounds and their use as enzyme inhibitors | |
| HK1198365A1 (en) | Imidazopyridine compounds, compositions and methods of use | |
| HK1199024A1 (en) | Novel morpholinyl derivatives useful as mogat-2 inhibitors mogat-2 | |
| ZA201309171B (en) | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors |